bluebird bio, Inc. (BLUE) is down 40.17 percent during Friday's trading, falling $2.83 to trade at $4.21 after announcing a definitive agreement to be acquired by Carlyle and SK Capital Partners.
The stock opened at $4.91 and has traded between $4.00 and $5.65 today. Volume has surged to 4.27 million shares, well above its average of 392,053. BLUE's 52-week range is $4.00 to $38.40.
The deal includes a leadership transition, with David Meek expected to become CEO upon closing.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.